Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
- Sponsor
- University of Zurich
- Study ID
- NCT01443676
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab — DRUGBevacizumab will be added to radiotherapy
- Radiation therapy — RADIATIONRadiation therapy
Study Details
The purpose of this study is to explore the efficacy of bevacizumab combined with radiotherapy compared with radiotherapy alone in the treatment of newly diagnosed glioblastoma in the elderly. * Trial with medicinal product
Key Dates
- First listed
- Sep 30, 2011
- Start date
- Oct 31, 2011
- Status verified
- Oct 2016
- Primary completion
- Aug 31, 2015
- Completion
- Aug 31, 2016
Study Design
- Enrollment
- 75 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: RadiotherapyRadiotherapy
- Experimental: Radiotherapy plus BevacizumabRadiotherapy plus Bevacizumab
Primary Outcome Measure
median overall survival [ Time Frame: 1 year ]
Related Studies
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York
- Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed GlioblastomaPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)PHASE2 · Recruiting · Patrick Wen, MD · Birmingham, Alabama
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBMPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York